Holen Sie sich die Stockscreener-App
0.9931
1.34%
0.0131
Vorhandelsmarkt:
.99
-0.0031
-0.31%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLS?
Forum
Prognose
Aktiensplit
Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Down 17.6% in December - MarketBeat
62,785 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Acquired by XTX Topco Ltd - Defense World
SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia - Marketscreener.com
SELLAS Life Sciences Advances Phase 3 AML Trial - TipRanks
SELLAS triggers interim analysis in AML trial - Investing.com
SELLAS triggers interim analysis in AML trial By Investing.com - Investing.com Canada
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - GlobeNewswire
SELLAS Life Sciences Hits Major Milestone in Phase 3 AML Cancer Treatment Trial - StockTitan
SELLAS reports promising AML drug trial results By Investing.com - Investing.com Canada
SELLAS reports promising AML drug trial results - Investing.com India
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML - The Manila Times
SELLAS Announces Positive Overall Survival and Overall - GlobeNewswire
SELLAS' SLS009 Triples Survival Time in Phase 2 AML Trial, Shows Breakthrough Response Rates - StockTitan
Anson Funds Management LP Purchases Shares of 793,835 SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - MarketBeat
SELLAS announces data indicating key predictor of response to SLS009 in solid cancers - Yahoo Finance
SELLAS Announces Positive Data from Preclinical Studies - GlobeNewswire
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor - The Bakersfield Californian
SELLAS Life Sciences' SLS009 Shows 67% Efficacy in ASXL1-Mutated Cancer Study | SLS Stock News - StockTitan
Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely - Simply Wall St
We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate - Yahoo Finance
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
SELLAS Reports 31% Response Rate in AML Trial, Narrows Q3 Loss to $7.1M | SLS Stock News - StockTitan
Highbridge Capital Management's Strategic Acquisition of SELLAS Life Sciences Shares - GuruFocus.com
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024 - GlobeNewswire
Northrop Grumman Corp (NOC-N) QuotePress Release - The Globe and Mail
SELLAS' Cancer Drug Shows 50% Response Rate in Leukemia Trial, Doubles Survival Time | SLS Stock News - StockTitan
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Decrease in Short Interest - MarketBeat
Galinpepimut-S Gets Rare Pediatric Disease Designation for AML - Hematology Advisor
FDA grants rare pediatric disease designation to SELLAS cancer drug By Investing.com - Investing.com Australia
SELLAS Announces U.S. FDA Rare Pediatric Disease - GlobeNewswire
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S - The Bakersfield Californian
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia - StockTitan
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - GlobeNewswire
Trading Day Triumph: SELLAS Life Sciences Group Inc (SLS) Ends at 1.19, a -2.46 Surge/Plunge - The Dwinnex
Nvidia Corp (NVDA-Q) QuotePress Release - The Globe and Mail
SELLAS extends Times Square lease through 2026 - Investing.com
SELLAS extends Times Square lease through 2026 By Investing.com - Investing.com Australia
What is SELLAS Life Sciences Group Inc (SLS) Stock Return on Shareholders’ Capital? - SETE News
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 0.8% - MarketBeat
Acute Myeloid Leukemia Market Trends, Key Drivers, Opportunities, Leading Players And Forecast To 2033 - WhaTech
Biotech Soars On Material Transfer Agreement - Invezz
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Lombard Odier Asset Management Europe Ltd Sells 15,000 Shares of StoneCo Ltd. (NASDAQ:STNE) - Defense World
Seelos Therapeutics surges on deal with U.S. Army to develop PTSD drug - XM
Steniel Manufacturing board clears share offering to raise up to P315m - manilastandard.net
How did SELLAS Life Sciences Group Inc (SLS) fare last session? - US Post News
SLM price target lowered to $26 from $29 at Wedbush - TipRanks
Setna iO announces new UK headquarters - AviTrader
Inspire Investing LLC Boosts Stake in Silicon Laboratories Inc. (NASDAQ:SLAB) - Defense World
Australia's Stelar Metals rises on copper, silver find - XM
Quarterly Metrics: Quick and Current Ratios for SELLAS Life Sciences Group Inc (SLS) - The Dwinnex
Investor’s Delight: ENDRA Life Sciences Inc (NDRA) Closes Weak at 0.20, Down -6.77 - The Dwinnex
Ready to Jump After Recent Trade: SELLAS Life Sciences Group Inc (SLS) - SETE News
Oman India Investment Fund sells shares worth Rs 75 cr in Senco Gold - The Economic Times
1.76%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):